Amlodipine + Olmesartan Medoxomil

Welcome to Dwaey, specifically on Amlodipine + Olmesartan Medoxomil page.
This medicine contains important and useful components, as it consists of
Amlodipine + Olmesartan Medoxomil is available in the market in concentration.

Generic Name of Amlodipine + Olmesartan Medoxomil - Learn More

Amlodipine + Olmesartan Medoxomil

Amlodipine + Olmesartan Medoxomil Precaution - What You Need to Know

The combination of amlodipine and olmesartan medoxomil is typically used for the treatment of hypertension. This combination benefits patients by addressing blood pressure from two different mechanisms: amlodipine, a calcium channel blocker, and olmesartan, an angiotensin II receptor blocker (ARB). However, certain precautions must be observed:

- Renal Function: Both amlodipine and olmesartan can affect renal function. Olmesartan, as an ARB, can cause hyperkalemia, particularly in patients with pre-existing renal issues. Regular monitoring of renal function and electrolytes, especially potassium levels, is critical, particularly in those with kidney disease or elderly patients.
- Hypotension: Amlodipine can lead to vasodilation, potentially causing hypotension, especially in patients who are volume-depleted or on diuretics. It is essential to monitor blood pressure frequently after initiating therapy, especially for patients who may be more prone to low blood pressure, such as the elderly.
- Pregnancy and Breastfeeding: This combination is contraindicated during pregnancy (especially in the second and third trimesters) as olmesartan may cause fetal harm, including renal failure and low blood pressure in the fetus. Amlodipine is Category C, and while less studied in pregnancy, should also be avoided. Both drugs are excreted in breast milk, and breastfeeding is not recommended during therapy.
- Angioedema: Though rare, ARBs such as olmesartan can cause angioedema (swelling of the face, tongue, or throat), which may be life-threatening. Immediate medical attention is needed if such symptoms occur.

Amlodipine + Olmesartan Medoxomil Indication - Uses and Benefits

The combination of amlodipine and olmesartan medoxomil is primarily indicated for the management of essential hypertension (high blood pressure). Amlodipine works as a calcium channel blocker that relaxes blood vessels, leading to a reduction in blood pressure. Olmesartan, an angiotensin II receptor blocker (ARB), inhibits the vasoconstrictive effects of angiotensin II, further lowering blood pressure.

This dual approach to hypertension is effective in controlling blood pressure when monotherapy is inadequate. Olmesartan is particularly useful in reducing the risk of stroke and kidney damage associated with high blood pressure, while amlodipine provides additional benefits in terms of reducing the risk of heart failure and ischemic heart disease.

There is also off-label use in patients with heart failure, especially when there is concomitant hypertension. However, it is generally considered when more comprehensive management is needed, including lifestyle changes and diuretics.

Amlodipine + Olmesartan Medoxomil Contraindications - Important Warnings

This combination therapy is contraindicated in certain conditions due to the risks associated with both medications:

- Hypersensitivity: Contraindicated in individuals who have a known hypersensitivity to amlodipine or olmesartan or any component of the formulation.
- Pregnancy: Both amlodipine and olmesartan should be avoided during pregnancy, especially in the second and third trimesters, as olmesartan can cause serious fetal harm. Amlodipine is not recommended during pregnancy either.
- Renal Artery Stenosis: The combination is contraindicated in patients with bilateral renal artery stenosis (narrowing of both renal arteries), as both drugs can reduce kidney function and potentially lead to renal failure.
- Severe Hepatic Impairment: Amlodipine and olmesartan should be used with caution or avoided in patients with severe hepatic impairment, as both drugs may accumulate to dangerous levels in such individuals.
- Angioedema History: A history of angioedema, especially associated with ACE inhibitors or other ARBs, is a contraindication due to the risk of recurrence.

Amlodipine + Olmesartan Medoxomil Side Effects - What to Expect

Common side effects of amlodipine and olmesartan medoxomil are generally mild but can include:

- Amlodipine: Dizziness, swelling (particularly in the ankles and feet), flushing, headache, and palpitations are common. Rare side effects include gingival hyperplasia (gum overgrowth) and liver dysfunction.
- Olmesartan: Can cause dizziness, especially when standing up quickly, and fatigue. Serious but rare side effects include hyperkalemia (elevated potassium levels), hypotension, and angioedema (swelling of the face, lips, throat). Chronic diarrhea and weight loss have been reported in association with olmesartan (olmesartan-induced enteropathy).
- Combination Side Effects: When used together, amlodipine and olmesartan can increase the risk of hypotension, particularly in volume-depleted patients or those on other antihypertensive therapy. The combination can also elevate the risk of electrolyte imbalances, such as hyperkalemia.

Monitoring for adverse effects, particularly when starting therapy or adjusting doses, is important for ensuring patient safety. If severe side effects like angioedema, severe dizziness, or chest pain occur, the patient should seek immediate medical attention.

Amlodipine + Olmesartan Medoxomil Pregnancy Category ID - Safety Information

17

Amlodipine + Olmesartan Medoxomil Mode of Action - How It Works

Amlodipine and olmesartan work together to lower blood pressure through complementary mechanisms:

- Amlodipine is a calcium channel blocker that inhibits the influx of calcium ions into vascular smooth muscle cells, leading to vasodilation (relaxation of blood vessels). This reduces vascular resistance and lowers blood pressure. It also helps relieve chest pain (angina) by improving coronary blood flow.
- Olmesartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to its receptors, leading to vasodilation. By blocking angiotensin II, olmesartan reduces the effects of this potent vasoconstrictor, thus lowering blood pressure and decreasing the workload on the heart. ARBs like olmesartan are also renoprotective and beneficial in patients with hypertension and diabetes.

Together, these two medications provide a dual approach to managing hypertension, addressing both vascular tone (via amlodipine) and the hormonal regulation of blood pressure (via olmesartan).

Amlodipine + Olmesartan Medoxomil Drug Interactions - What to Avoid

Amlodipine and olmesartan can interact with other medications, potentially altering their effectiveness or increasing the risk of adverse effects.

- Other Antihypertensives: When used in conjunction with other antihypertensive agents (such as diuretics or beta-blockers), there is an increased risk of additive hypotension. Careful monitoring of blood pressure is necessary to avoid excessive drops in blood pressure, particularly after the first dose.
- Potassium-Sparing Diuretics or Potassium Supplements: Because olmesartan can increase potassium levels, the addition of potassium-sparing diuretics (e.g., spironolactone) or potassium supplements should be avoided unless closely monitored to prevent hyperkalemia.
- NSAIDs (Non-Steroidal Anti-Inflammatory Drugs): The concurrent use of NSAIDs (e.g., ibuprofen, naproxen) can reduce the effectiveness of olmesartan and may lead to kidney damage, especially in elderly patients. This is due to NSAIDs’ potential to impair renal blood flow and the kidney-protective effects of ARBs.
- Cytochrome P450 Interactions: Amlodipine is metabolized by CYP3A4 enzymes. Medications that inhibit or induce this enzyme, such as ketoconazole (CYP3A4 inhibitor) or rifampin (CYP3A4 inducer), can increase or decrease amlodipine levels, respectively. Adjustments in dose may be required when these drugs are used together.
- Lithium: Concurrent use of amlodipine or olmesartan with lithium may increase the risk of lithium toxicity, necessitating close monitoring of lithium levels.

Amlodipine + Olmesartan Medoxomil Pregnancy Category Note - Key Information

Pregnancy Category: C (1st trimester); D (2nd & 3rd trimesters).

Amlodipine + Olmesartan Medoxomil Adult Dose - Recommended Dosage

The usual starting dose of amlodipine is 5 mg once daily, which can be increased to a maximum of 10 mg once daily depending on the patient’s blood pressure response and tolerability. Olmesartan is typically started at 20 mg once daily, and the dose may be increased to 40 mg once daily depending on the therapeutic response. When combined, these medications are available in fixed-dose formulations, such as amlodipine 5 mg + olmesartan 20 mg or amlodipine 5 mg + olmesartan 40 mg.

The goal of therapy is to achieve and maintain blood pressure within the normal range. Blood pressure should be regularly monitored to adjust doses as needed.

Amlodipine + Olmesartan Medoxomil Child Dose - Dosage for Children

The combination of amlodipine and olmesartan is not typically recommended for pediatric patients under 18 years of age, as safety and efficacy have not been established in this population. Amlodipine can be used in children aged 6 years and older for hypertension, starting at 2.5 mg once daily and titrating as needed based on blood pressure. Olmesartan is also used off-label for pediatric hypertension, but dosing should be adjusted based on the child’s weight and renal function, and careful monitoring is required to prevent adverse effects like hyperkalemia.

Given the potential for serious side effects and the need for individualized dosing, pediatric patients should only receive this combination under careful medical supervision.

Amlodipine + Olmesartan Medoxomil Renal Dose - Dosage for Kidney Conditions

In patients with mild to moderate renal impairment (creatinine clearance 30-60 mL/min), the dose of amlodipine typically does not require adjustment. However, olmesartan should be started at a lower dose (e.g., 20 mg once daily) and may need to be adjusted based on the patient's response and renal function. Severe renal impairment (creatinine clearance < 30 mL/min) may require avoidance of olmesartan, as it can cause further deterioration in renal function.

Frequent monitoring of kidney function (serum creatinine, estimated glomerular filtration rate) and electrolytes is necessary to avoid complications in patients with renal impairment.